Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe et al. · The Lancet Oncology · 2009
Cited by 4,084 works. doi:10.1016/s1470-2045(09)70364-x
Authors
- Tetsuya Mitsudomi
- Satoshi Morita
- Yasushi Yatabe
- Shunichi Negoro
- Isamu Okamoto
- Junji Tsurutani
- Takashi Seto
- Miyako Satouchi
- Hirohito Tada
- Tomonori Hirashima
- Nobuyuki Katakami
- Minoru Takada
- Hiroshige Yoshioka
- Kazuhiko Shibata
- Shinzoh Kudoh
- Eiji Shimizu
- Hiroshi Saito
- Shinichi Toyooka
- Kazuhiko Nakagawa
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Cancer Statistics, 2009
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer